BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/29/23
BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023GlobeNewsWire • 03/27/23
BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic FibrosisGlobeNewsWire • 02/22/23
BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on BacteriophageGlobeNewsWire • 11/29/22
BiomX Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/09/22
BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022GlobeNewsWire • 11/02/22
BiomX Inc. (PHGE) CEO Jonathan Solomon on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
BiomX Reports Second Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 08/10/22
BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022Business Wire • 08/07/22
BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel DiseaseBusiness Wire • 08/04/22
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome BiomarkersBusiness Wire • 06/28/22
BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic FibrosisBusiness Wire • 06/27/22
BiomX Inc. (PHGE) CEO Jonathan Solomon on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
BiomX Reports First Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 05/11/22
BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis PatientsBusiness Wire • 05/06/22